| Year |
Citation |
Score |
| 2021 |
Chessari G, Hardcastle IR, Ahn JS, Anil B, Anscombe E, Bawn RH, Bevan LD, Blackburn TJ, Buck I, Cano C, Carbain B, Castro J, Cons B, Cully SJ, Endicott JA, et al. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction. Journal of Medicinal Chemistry. PMID 33761253 DOI: 10.1021/acs.jmedchem.0c02188 |
0.377 |
|
| 2016 |
Coxon CR, Anscombe E, Harnor SJ, Martin MP, Carbain BJ, Golding BT, Hardcastle IR, Harlow LK, Korolchuk S, Matheson CJ, Newell DR, Noble ME, Sivaprakasam M, Tudhope SJ, Turner DM, et al. Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry. PMID 28005359 DOI: 10.1021/Acs.Jmedchem.6B01254 |
0.455 |
|
| 2015 |
Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble ME, Wedge SR, et al. Identification and Characterization of an Irreversible Inhibitor of CDK2. Chemistry & Biology. PMID 26320860 DOI: 10.1016/J.Chembiol.2015.07.018 |
0.47 |
|
| 2014 |
Carbain B, Paterson DJ, Anscombe E, Campbell AJ, Cano C, Echalier A, Endicott JA, Golding BT, Haggerty K, Hardcastle IR, Jewsbury PJ, Newell DR, Noble ME, Roche C, Wang LZ, et al. 8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode. Journal of Medicinal Chemistry. 57: 56-70. PMID 24304238 DOI: 10.1021/Jm401555V |
0.41 |
|
| Show low-probability matches. |